Collaboration with Huwel Lifesciences strengthened to commercialise compact RT-PCR system Cubo
The company and Huwel Lifesciences are strengthening their collaboration to build a nationwide sales and distribution platform for Cubo, Huwel's ultra-compact RT-PCR system.
What was announced
The company issued a press release saying it and Huwel Lifesciences are strengthening their collaboration to build a nationwide commercialisation platform for Cubo, Huwel's ultra-compact RT-PCR system.
What Cubo is
- RT-PCR is a molecular test method usually run in large centralised laboratories.
- Cubo's ultra-compact design is intended to allow such testing in smaller, more decentralised healthcare settings, including Tier-II and Tier-III locations.
How the two plan to work together
- Establish a dedicated sales and distribution infrastructure.
- Recruit senior sales leadership and form specialised sales teams.
- Develop strategic channel partnerships.
- Initial focus on Cubo, with scope to commercialise Huwel's broader molecular diagnostics portfolio.
- Support through product demonstrations, installation support and ongoing customer engagement.
Who they aim to sell to
Private hospitals, diagnostic chains, independent laboratories, medical colleges, research institutions and other healthcare establishments in India's private healthcare sector.
Recurring revenue idea
Beyond placing instruments, the companies intend to build an ecosystem of compatible molecular assays and consumables that can support recurring testing requirements, so an installed Cubo could serve multiple testing needs.
Context for investors
The company describes itself as a diversified platform across Financial Inclusion & Digital Services, Agri Supply Chain & Technologies, and Diagnostics & Healthcare. This step extends its diagnostics push. The Managing Director framed it as building the commercial infrastructure and market coverage needed for adoption at scale.
How it may be read
The language is about plans and intentions — recruitment, distribution build-out and market coverage — rather than completed orders or revenue. Investors may watch for the pace of hiring, distribution tie-ups and actual Cubo installations in coming quarters.
Also from Avio Smart Market Stack
Corrigendum to 34th AGM Notice: Preferential Issue Price Revised to Rs. 7.73 per Share
25 Sep 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.